Search

Your search keyword '"Haas, Judith"' showing total 298 results
Start Over Author "Haas, Judith"
298 results on '"Haas, Judith"'

5. Autorenverzeichnis

Author

Aktas, Orhan, primary, Alvermann, Sascha, additional, Brück, Wolfgang, additional, Faiss, Jürgen, additional, Fitzner, Brit, additional, Flachenecker, Peter, additional, Gärtner, Jutta, additional, Gerken, Jeanine, additional, Haas, Judith, additional, Haase, Rocco, additional, Hardt, Cornelia, additional, Haupts, Michael, additional, Hecker, Michael, additional, Hoffmann, Frank A., additional, Hoppenworth, Uwe, additional, Huppke, Peter, additional, Köhler, Wolfgang, additional, Krumbholz, Markus, additional, Kunkel, Annett, additional, Laurent, Sarah, additional, Linke, Ernst, additional, Löbermann, Micha, additional, Martin, Roland, additional, Meinl, Edgar, additional, Pöhlau, Dieter, additional, Reinshagen, Alexander, additional, Rieckmann, Peter, additional, Rommer, Paulus S., additional, Schifferdecker, Michael, additional, Schipper, Sabine, additional, Schippling, Sven, additional, Schmidt, Rudolf M., additional, Sinnecker, Tim, additional, Sokol, Christina, additional, Stadelmann-Nessler, Christine, additional, Stangel, Martin, additional, Temmes, Herbert, additional, Tumani, Hayrettin, additional, van der Meer, Franziska, additional, Voigt, Isabel, additional, Warnke, Clemens, additional, Winkelmann, Alexander, additional, Zettl, Uwe K., additional, Ziemssen, Tjalf, additional, Zimmermann, Klaus, additional, and Zipp, Frauke, additional

Published
2022
Full Text
View/download PDF

6. Pathophysiologisch ansetzende Therapie

Author

Alvermann, Sascha, primary, Faiss, Jürgen H., additional, Haas, Judith, additional, Hoffmann, Frank A., additional, Köhler, Wolfgang, additional, Martin, Roland, additional, Pöhlau, Dieter, additional, Schippling, Sven, additional, and Stangel, Martin, additional

Published
2022
Full Text
View/download PDF

7. Long‑term real‑world effectiveness and safety of fingolimod over 5 years in Germany

Author

Ziemssen, Tjalf, Lang, Michael, Schmidt, Stephan, Albrecht, Holger, Klotz, Luisa, Haas, Judith, Lassek, Christoph, Lang, Stefan, Winkelmann, Veronika E., Ettle, Benjamin, Schulze‑Topphoff, Ulf, Ziemssen, Tjalf, Lang, Michael, Schmidt, Stephan, Albrecht, Holger, Klotz, Luisa, Haas, Judith, Lassek, Christoph, Lang, Stefan, Winkelmann, Veronika E., Ettle, Benjamin, and Schulze‑Topphoff, Ulf

Abstract

Objective: To evaluate the 5-year real-world benefit–risk profile of fingolimod in patients with relapsing–remitting MS (RRMS) in Germany. Methods: Post-Authorization Non-interventional German sAfety study of GilEnyA (PANGAEA) is a non-interventional realworld study to prospectively assess the effectiveness and safety of fingolimod in routine clinical practice in Germany. The follow-up period comprised 5 years. Patients were included if they had been diagnosed with RRMS and had been prescribed fingolimod as part of clinical routine. There were no exclusion criteria except the contraindications for fingolimod as defined in the European label. The effectiveness and safety analysis set comprised 4032 and 4067 RRMS patients, respectively. Results: At the time of the 5-year follow-up of PANGAEA, 66.57% of patients still continued fingolimod therapy. Annualized relapse rates decreased from baseline 1.5 ± 1.15 to 0.42 ± 0.734 at year 1 and 0.21 ± 0.483 at year 5, and the disability status remained stable, as demonstrated by the Expanded Disability Status Scale mean change from baseline (0.1 ± 2.51), the decrease of the Multiple Sclerosis Severity Score from 5.1 ± 2.59 at baseline to 3.9 ± 2.31 at the 60-months follow-up, and the percentage of patients with ‘no change’ in the Clinical Global Impression scale at the 60-months follow-up (78.11%). Adverse events (AE) occurring in 75.04% of patients were in line with the known safety profile of fingolimod and were mostly non-serious AE (33.62%) and non-serious adverse drug reactions (50.59%; serious AE 4.98%; serious ADR 10.82%). Conclusions: PANGAEA demonstrated the sustained beneficial effectiveness and safety of fingolimod in the long-term realworld treatment of patients with RRMS.

Published
2024

11. "So at least now I know how to deal with things myself, what I can do if it gets really bad again"—experiences with a long-term cross-sectoral advocacy care and case management for severe multiple sclerosis: a qualitative study.

Author

Müller, Anne, Hebben, Fabian, Dillen, Kim, Dunkl, Veronika, Goereci, Yasemin, Voltz, Raymond, Löcherbach, Peter, Warnke, Clemens, Golla, Heidrun, Müller, Dirk, Hobus, Dorthe, Bonmann, Eckhard, Schwartzkopff, Franziska, Nelles, Gereon, Palmbach, Gundula, Temmes, Herbert, Franke, Isabel, Haas, Judith, Strupp, Julia, and Gerbershagen, Kathrin

Subjects
MULTIPLE sclerosis, QUALITATIVE research, CAREGIVERS, MEDICAL care, SEMI-structured interviews
Abstract

Background: Persons with severe Multiple Sclerosis (PwsMS) face complex needs and daily limitations that make it challenging to receive optimal care. The implementation and coordination of health care, social services, and support in financial affairs can be particularly time consuming and burdensome for both PwsMS and caregivers. Care and case management (CCM) helps ensure optimal individual care as well as care at a higher-level. The goal of the current qualitative study was to determine the experiences of PwsMS, caregivers and health care specialists (HCSs) with the CCM. Methods: In the current qualitative sub study, as part of a larger trial, in-depth semi-structured interviews with PwsMS, caregivers and HCSs who had been in contact with the CCM were conducted between 02/2022 and 01/2023. Data was transcribed, pseudonymized, tested for saturation and analyzed using structuring content analysis according to Kuckartz. Sociodemographic and interview characteristics were analyzed descriptively. Results: Thirteen PwsMS, 12 caregivers and 10 HCSs completed interviews. Main categories of CCM functions were derived deductively: (1) gatekeeper function, (2) broker function, (3) advocacy function, (4) outlook on CCM in standard care. Subcategories were then derived inductively from the interview material. 852 segments were coded. Participants appreciated the CCM as a continuous and objective contact person, a person of trust (92 codes), a competent source of information and advice (on MS) (68 codes) and comprehensive cross-insurance support (128 codes), relieving and supporting PwsMS, their caregivers and HCSs (67 codes). Conclusions: Through the cross-sectoral continuous support in health-related, social, financial and everyday bureaucratic matters, the CCM provides comprehensive and overriding support and relief for PwsMS, caregivers and HCSs. This intervention bears the potential to be fine-tuned and applied to similar complex patient groups. Trial registration: The study was approved by the Ethics Committee of the University of Cologne (#20–1436), registered at the German Register for Clinical Studies (DRKS00022771) and in accordance with the Declaration of Helsinki. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

Author

Correale, Jorge, Caride, Alejandro, Deri, Norma H., Ballario, Carlos, Broadley, Simon, Kneebone, Chris, Barnett, Michael, Pollard, John, Hodgkinson, Suzanne, Kermode, Allan, Macdonell, Richard, King, John, Butzkueven, Helmut, Lechner-Scott, Jeannette, Saines, Noel, Slee, Mark, Plummer, Chris, Willekens, Barbara, Vanopdenbosch, Ludo, Belachew, Shibeshih, Phan-Ba, Rémy, Delvaux, Valérie, Bissay, Veronique, Debruyne, Jan, Decoo, Danny, Crols, Roeland, Symons, Anoek, Nagels, Guy, Van Pesch, Vincent, Sindic, Christian, Dubois, Benedicte, Medaer, Robert, D'Hooghe, Marie, Guillaume, Daniel, De Smet, Eric, Seeldrayers, Pierrette, Lysandropoulos, Andreas, Vokaer, Mathieu, Geens, Karine, Willems, Christina, Denayer, Pierre, Bureau, Michel, Retif, Cecile, Dupuis, Michel, Bouquiaux, Olivier, Vanderdonckt, Patrick, van Landegem, William, Caekebeke, Jo, Van Ingelghem, Erwin, Peeters, Katelijne, Gerard, Pascale, de Noordhout, Alain Maertens, Desfontaines, Philippe, Urbain, Etienne, Declercq, Inge, Van Wijmeersch, Bart, Vanroose, Erwin, Wibail, Alain, Barthomolé, Emmanuel, Ursell, Melanie, Sweet, Margaret Elizabeth, Howse, David, Jichici, Draga, Shawush, Melad, Namaka, Mike, Traboulsee, Anthony, Hashimoto, Stan, Lo, Raymond, Marchetti, Paul, Lapierre, Yves, Jacques, Francois, MacLean, Gregg, Bhan, Virender, Duquette, Pierre, Stewart, Bradley, Paulseth, John, Kremenchutzky, Marcelo, Vorobeychik, Galina, O'Connor, Paul, Grand'Maison, François, Havrdova, Eva, Meluzinová, Eva, Valis, Martin, Talab, Radomír, Stourac, Pavel, Zapletalová, Olga, Dufek, Michal, Sládková, Vladimíra, Novotna, Alena, Vancurová, Romana, Lhotaková, Libuse, Fiedler, Jiri, Vachova, Marta, Dolezil, David, Stetkarova, Ivana, Rehankova, Adela, Psenica, Petr, Ulehlova, Veronika, Feketova, Sona, Skoda, Ondrej, Färkkilä, Markus, Taneli, Sarasoja, Koivisto, Keijo, Seppä, Juha Matti, Airas, Laura, Elovaara, Irina, Hartikainen, Päivi, Pirttila, Tuula, Louchart, Pierre, Ille, Olivier, Thenint, Jean philippe, Godet, Etienne, Vioud, Marcel Maillet, Colamarino, Renato, Gugenheim, Michel, Grimaud, Jerome, Kopf, Audrey, Billy, Christophe, Huttin, Bernard, Borsotti, Jean paul, Devos, Philippe, Kendjuo, Jean bertin N, Verier, Albert, Chapuis, Stephane, Daluzeau, Nathalie, Angibaud, Gilles, Uriot, Marie-Sylvie Artaud, Ziegler, François, Sellal, François, Moulignier, Antoine, Lavenu, Isabelle, Ismail, Samir, Devy, Richard, Suceveanu, Manuel, Wagner, Marc, Marcel, Sebastien, Derouiche, Faycal, Mostoufizadehghalamfarsa, Sohrab, Delalande, Sophie, Ruggieri, Irene, Van Nieuwenhuyse, Catherine Bossu, Nifle, Chantal, Ondze, Basile, Vasilescu, Carmen Gurau, Vongsouthi, Cyrille, Coustans, Marc, Anne, Olivier, Amevigbe, Josephine, Servan, Jerome, Merienne, Marc, Eck, Philippe, Berroir, Stephane, Busson, Philippe, Barroso, Bruno, Larrieu, Jean-Marc, Giendaj, Catherine Louvet, Malkoun, Imad, Hautecoeur, Patrick, Kwiatkowski, Arnaud, Pouliquen, Andre, Garrigues, Guillaume, Delerue, Olivier, Giraud, Pierric, Gere, Julien, Vaunaize, Jean, Dereeper, Olivier, Seiller, Nicolas, Alsassa, Roger, Vlaicu, Mihaela, Neuville, Veronique, Faucheux, Jean Marc, Bernady, Patricia, Fanjaud, Guy, Viallet, François, Schroeter, Michael, Schlemilch-Paschen, Sylke, Lange, Thomas, Bohr, Kin-Arno, Jendroska, Klaus, Rehkopf, Elisabeth, Bergmann, Arnfin, Kleinschnitz, Christoph, Postert, Thomas, Scholz, Peter, Mauz, Uwe, Stratmann, Hubert, Siefjediers, Veneta, Prantl, Martin, Gehring, Klaus, Zellner, Ruth, Junge, Kathrin, Zellner, Anton, Bacay, Valerina, Schlegel, Eugen, Polzer, Udo, Strauss, Erik, Link, Andreas, Stenzel, Christoph, Freidel, Matthias, Drews, Joachim, Neudert, Christian, Schmitz, Frank, Jaeger, Joachim, Masri, Said, Heuberger, Wolfgang, Trausch, Beate, Ruhnke, Oliver, Scarel, Serena, Bach, Kathlen, Ernst, Michael, Landefeld, Harald, Richter, Nils, Schmidt, Stephan, Krause, Michaela, Dressel, Alezander, Ruth, Roland, Anvari, Kerstin, Gossling, Jens, Schenk, Christoph, Tiedge, Oliver, Bode, Lutz, Eder, Hans-Thomas, Pfeffer, Oliver, Krug, Reinhard, Lassek, Christoph, Fleischer, Eberhard, Meuth, Sven, Klotz, Luisa Hildegard, Peglau, Ines, Kukowski, Borries, Herting, Birgit, Guthke, Kersten, Schierenbeck, Jurgen, Brockmeier, Bernd, Albrecht, Holger, Wuttke, Matthias, Augspach-Hofmann, Regine, Gunther, Stefan, Redbrake, Martin, Franke, Christian, Buchner, Klaus, Gratz, Thomas, Horn, Rolf, Doemges, Frank, Schreiber, Martin, Brosch, Thomas, Horn, Markus, Kittlitz, Matthias, Vulturius, Gabriele, Hinse, Paul, Malessa, Rolf, Wiehler, Stephan, Katsarava, Zaza, Kastrup, Oliver, Kausch, Ulrich, Gullekes, Martin, Fickinger, Markus, Wenzel, Wilhelm, Botefur, Ingolf C., Reifschneider, Gerd, Rauer, Sebastian, Lang, Michael, Harms, Lutz, Eckhardt, Ulrich, Cursiefen, Simone, Linker, Ralf, Angstwurm, Klemens, Haas, Judith, Schuetze, Ivo, Rohm, Eva, Stienker-Fisse, H., Sailer, Michael, Bohringer, Johannes, Maurer, Mathias, Bause, Eberhard, Wersching, Ronald, Dachsel, Reinhardt, Domke, Sylke, Hoffman, Frank, Tackenberg, Bjorn, Roch, Kerstin, Ziebold, Uwe, Kallmann, Boris, Buehler, Bernhard, Faiss, Judith, Faiss, Juergen, Schimrigk, Sebastian, Menges, Christian, Knop, Karl Christian, Koehler, Wolfgang, Siever, Arno, Bufler, Johannes, Gramsl, Georg, Kuhnler, Benedicta, Maschke, Matthias, Stogbauer, Florian, Staude, Lisa, Bethke, Florian, Bitsch, Andreas, Harmjanz, Arndt D., Windsheimer, Jorg, Kieseier, Bernd C., Berkenfeld, Ralf, Tumani, Hayrettin, Kirsch, Michael, Wildemann, Brigitte, Daniels, Regina, Gottwald, Klaus, Elias, Wolfgang-Gerhard, Hoffmann, Olaf, Schwab, Matthias, Pilz, Christopher, Klostermann, Fabian, Hellwig, Kerstin, Berthele, Achim, Bayas, Antonios, Molitor, Daniel, Grothe, Christoph, Wagner, Bert, Karageorgiou, Klimentini, Mitsikostas, Dimosthenis, Kodounis, Antonios, Plaitakis, Andreas, Papadimitriou, Alexandros, Grigoriadis, Nikolaos, Vlaikidis, Nikolaos, Koutlas, Evaggelos, Kyritsis, Athanassios, Papathanassopoulos, Panagiotis, Makris, Nikolaos, Tavernarakis, Antonios, Scarpini, Elio, Montanari, Enrico, Marrosu, Maria Giovanna, Trojano, Maria, Amato, Maria Pia, Rottoli, Mariarosa, Lugaresi, Alessandra, Florio, Ciro, Gasperini, Claudio, Grimaldi, Luigi, Millefiorini, Enrico, Koudriavtseva, Tatiana, Perla, Franco, Mantegazza, Renato, Bertolotto, Antonio, Ghezzi, Angelo, Aguilar, Sandra Quinones, Eisenberg, Eli Skromne, Lopez, Leondardo Llamas, Estudillo, Rocio Marquez, Schrijver, H.M., Wittebol, M.C., Baart, J.C., van Golde, A.E.L., Hengstman, G.J.D., Pop, P.H.M., Bos (Geldrop), M., Medaer, R., Schyns-Soeterboek, Angelique, van der Zwart, A., van Diepen, A.J.H., Verheul, G.A.M., Verhagen, W.I.M., Bos (Helmond), M., Witjes, R.J.G.M., Sinnige, L.G.F., van Munster, E.Th.L., Sanders, E.A.C.M., van Dijl, Ron, Hupperts, R.M.M., Frequin, S.T.F.M., Visser, L.H., Henselmans, J.M.L., Moll, J.W.B., Midgard, Rune, Myhr, Kjell Morten, Edland, Astrid, Telstad, Wenche, Hognestad, Tone, Lund, Christian, Hovdal, Harald, Kamaljit, Kaur, Schepel, Jan, Hogenesch, Roelfien Ida, Schüler, Stephan, Odeh, Francis, Alstadhaug, Karl B., Korsgaard, Olav, Farbu, Elisabeth, Ingvaldsen, Teis Barclay, Soares (SCO), Diana, Rente, José, Guerra, José Manuel Costa, Morganho, Armando, Leitão, António, de Sá, João, Sá, Maria José, Marques, Pinto, Veloso, Mário, Baptista, Miguel Viana, Szilasiová, Jarmila, Copikova-Cudrakova, Daniela, Prochazkova, Lubica, Klimová, Eleonóra, Donath, Vladimir, Brozman, Miroslav, Ramo, Cristina, Ruiz, Domingo Pérez, Hernández, Carmen Calles, Sola, María Eugenia Marzo, Moro, Roberto Suarez, Vidal, Jose Antonio, Rodríguez, Ana Belén Caminero, Ozaeta, Gisela Martin, Nadal, Jordi Batlle, Esquide, Amaya Alvarez de Arcaya, Urtaza, Javier Olascoaga, Martínez-Yélamos, Sergio, Arbizu, Txomin, Torrenta, Lluis Ramio i, Boggild, Mike, Wilson, Martin, Al-Araji, Adnan, Nicholas, Richard, Harrower, Timothy, Redmond, Ian, Wolf, Tilo, Osei-Bonsu, Michael, Mazibrada, Gordon, Rog, David, Cottrell, David, Constantinescu, Cris, Gray, Orla, Belhag, Mohamed, Shehu, Abdullah, Rashid, Waqar, Duddy, Martin, Kappos, Ludwig, Wiendl, Heinz, Spelman, Tim, Pellegrini, Fabio, Chen, Yi, Dong, Qunming, and Koendgen, Harold

Published
2018
Full Text
View/download PDF

14. Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study

Author

Frahm, Niklas, primary, Fneish, Firas, additional, Ellenberger, David, additional, Haas, Judith, additional, Löbermann, Micha, additional, Peters, Melanie, additional, Pöhlau, Dieter, additional, Röper, Anna-Lena, additional, Schilling, Sarah, additional, Stahmann, Alexander, additional, Temmes, Herbert, additional, Paul, Friedemann, additional, and Zettl, Uwe Klaus, additional

Published
2023
Full Text
View/download PDF

15. Autorenverzeichnis

Author

Aktas, Orhan, primary, Alvermann, Sascha, additional, Block, Anja, additional, Brück, Wolfgang, additional, Faiss, Jürgen, additional, Fitzner, Brit, additional, Flachenecker, Peter, additional, Gärtner, Jutta, additional, Gerken, Jeanine, additional, Haas, Judith, additional, Hardt, Cornelia, additional, Haupts, Michael, additional, Hecker, Michael, additional, Hoffmann, Frank A., additional, Hoppenworth, Uwe, additional, Huppke, Peter, additional, Kern, Raimar, additional, Köhler, Wolfgang, additional, Krumbholz, Markus, additional, Kunkel, Annett, additional, Linke, Ernst, additional, Martin, Roland, additional, Meinl, Edgar, additional, Pöhlau, Dieter, additional, Reinshagen, Alexander, additional, Rieckmann, Peter, additional, Sailer, Michael, additional, Schifferdecker, Michael, additional, Schipper, Sabine, additional, Schippling, Sven, additional, Schmidt, Rudolf, additional, Schmitt, Hendrik, additional, Sokol, Christina, additional, Stadelmann-Nessler, Christine, additional, Stangel, Martin, additional, Tumani, Hayrettin, additional, Zettl, Uwe K., additional, Ziemssen, Tjalf, additional, Zimmermann, Klaus, additional, Zipp, Frauke, additional, and Littig, Eva, additional

Published
2018
Full Text
View/download PDF

16. Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study.

Author

Fneish, Firas, Frahm, Niklas, Peters, Melanie, Ellenberger, David, Haas, Judith, Löbermann, Micha, Pöhlau, Dieter, Röper, Anna-Lena, Schilling, Sarah, Stahmann, Alexander, Temmes, Herbert, Paul, Friedemann, and Zettl, Uwe K.

Subjects
MULTIPLE sclerosis, BOOSTER vaccines, COVID-19 vaccines, LONGITUDINAL method, SCIENTIFIC observation, AUTOIMMUNE diseases
Abstract

Several studies reported post-SARS-CoV-2-vaccination (PV) symptoms. Even people with multiple sclerosis (PwMS) have concerns about disease activity following the SARS-CoV-2 vaccination. We aimed to determine the proportion of PwMS with PV relapses, the PV annualized relapse rate (ARR), the time from vaccination to subsequent relapses, and identify sociodemographic/clinical risk factors for PV relapses. PwMS were surveyed several times at baseline and four follow-ups as part of a longitudinal observational study regarding the safety and tolerability of the SARS-CoV-2 vaccination. The inclusion criteria for this analysis were age ≥18 years, ≥1 SARS-CoV-2 vaccination, and ≥1-year observation period since initial vaccination. Of 2466 PwMS, 13.8% reported PV relapses (mostly after second [N = 147] or booster vaccination [N = 145]) at a median of 8.0 (first/third quantile: 3.55/18.1) weeks PV, with the shortest period following initial vaccination (3.95 weeks). The ARR was 0.153 (95% confidence interval: 0.138–0.168), with a median observation period since initial vaccination of 1.2 years. Risk factors for PV relapses were younger age, female gender, moderate-severe disability levels, concurrent autoimmune diseases, relapsing-remitting MS courses, no DMT, and relapses within the year prior to the first vaccination. Patients' health conditions before/during initial vaccination may play a more important role in PV relapse occurrence than vaccination per se. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Organization of descending neurons in the brain of the desert locust.

Author

Staudacher, Erich M., Cigan, Michel‐Leon, Wenz, Felix, Pollun, Aleksandra, Beck, Sascha, Beck, Marius, Reh, Fabienne, Haas, Judith, and Homberg, Uwe

Abstract

In most animals, multiple external and internal signals are integrated by the brain, transformed and, finally, transmitted as commands to motor centers. In insects, the central complex is a motor control center in the brain, involved in decision‐making and goal‐directed navigation. In desert locusts, it encodes celestial cues in a compass‐like fashion indicating a role in sky‐compass navigation. While several descending brain neurons (DBNs) including two neurons transmitting sky compass signals have been identified in the locust, a complete analysis of DBNs and their relationship to the central complex is still lacking. As a basis for further studies, we used Neurobiotin tracer injections into a neck connective to map the organization of DBNs in the brain. Cell counts revealed a maximum of 324 bilateral pairs of DBNs with somata distributed in 14 ipsilateral and nine contralateral groups. These neurons invaded most brain neuropils, especially the posterior slope, posterior and ventro‐lateral protocerebrum, the antennal mechanosensory and motor center, but less densely the lateral accessory lobes that are targeted by central‐complex outputs. No arborizations were found in the central complex and only few processes in the mushroom body, antennal lobe, lobula, medulla, and superior protocerebrum. Double label experiments provide evidence for the presence of GABA, dopamine, tyramine, but not serotonin, in small sets of DBNs. The data show that some DBNs may be targeted directly by central‐complex outputs, but many others are likely only indirectly influenced by central‐complex networks, in addition to input from multiple other brain areas. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

Author

Ziemssen, Tjalf, Lang, Michael, Tackenberg, Björn, Schmidt, Stephan, Albrecht, Holger, Klotz, Luisa, Haas, Judith, Lassek, Christoph, Medin, Jennie, Cornelissen, Christian, and on behalf of the PANGAEA study group

Published
2017
Full Text
View/download PDF

20. SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study

Author

Frahm, Niklas, primary, Fneish, Firas, additional, Ellenberger, David, additional, Haas, Judith, additional, Loebermann, Micha, additional, Parciak, Tina, additional, Peters, Melanie, additional, Pöhlau, Dieter, additional, Rodgers, Jeff, additional, Röper, Anna-Lena, additional, Schilling, Sarah, additional, Stahmann, Alexander, additional, Temmes, Herbert, additional, Zettl, Uwe K., additional, and Middleton, Rodden M., additional

Published
2022
Full Text
View/download PDF

21. Prestatiedruk en schoolstress bekeken vanuit verschillende perspectieven

Author

Peeters, Margot, Doornwaard, Suzan, Leijerzapf, Maud, de Haas, Judith, Efat, Armaghan, Kleinjan, Marloes, Leerstoel Finkenauer, and Youth in Changing Cultural Contexts

Subjects
prestatiedruk, beschermende factoren, schoolstress, cocreatie, adolescenten
Abstract

Jongeren ervaren de laatste jaren steeds meer schoolstress en druk door school. Om goed inzicht te krijgen in de factoren die ten grondslag liggen aan deze toename en mogelijk een schakel zijn voor verandering, is het van belang om dit maatschappelijke probleem vanuit verschillende perspectieven te bekijken. In dit onderzoek verbinden we wetenschappelijke kennis (systematisch literatuuronderzoek) met praktijk- en ervaringskennis van professionals, beleidsmedewerkers, ouders en jongeren (diepte-interviews, n = 60). De resultaten van dit onderzoek laten zien dat de beschermende factoren op verschillende niveaus (systeem, directe omgeving, individu) met elkaar interacteren. De maatschappij legt veel nadruk op resultaat en prestaties, wat invloed heeft op de verwachtingen van jongeren en ouders, en de inrichting van ons onderwijssysteem. Scholen kunnen jongeren ondersteunen bij hun ontwikkeling door aandacht te besteden aan bredere talentontwikkeling, alternatieve beoordelingsvormen, goed mentorschap en de sociaal-emotionele ontwikkeling. Om de ervaren schoolstress en druk door school te verminderen is het belangrijk om niet alleen het individu weerbaarder te maken, maar ook de directe omgeving en de school/maatschappij mee te nemen in preventieve maatregelen om schoolstress en ervaren druk te minderen.

Published
2022

22. Prestatiedruk en schoolstress bekeken vanuit verschillende perspectieven

Author

Leerstoel Finkenauer, Youth in Changing Cultural Contexts, Peeters, Margot, Doornwaard, Suzan, Leijerzapf, Maud, de Haas, Judith, Efat, Armaghan, Kleinjan, Marloes, Leerstoel Finkenauer, Youth in Changing Cultural Contexts, Peeters, Margot, Doornwaard, Suzan, Leijerzapf, Maud, de Haas, Judith, Efat, Armaghan, and Kleinjan, Marloes

Published
2022

23. Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol

Author

Golla, Heidrun, Dillen, Kim, Hellmich, Martin, Dojan, Thomas, Ungeheuer, Solveig, Schmalz, Petra, Stass, Angelika, Mildenberger, Vanessa, Goereci, Yasemin, Dunkl, Veronika, Strupp, Julia, Fink, Gereon R., Voltz, Raymond, Stock, Stephanie, Cornely, Oliver, Stahmann, Alexander, Mueller, Anne, Loecherbach, Peter, Burghaus, Lothar, Limmroth, Volker, Bonmann, Eckhard, Gerbershagen, Kathrin, Nelles, Gereon, Joist, Thomas, Haas, Judith, Temmes, Herbert, Warnke, Clemens, Golla, Heidrun, Dillen, Kim, Hellmich, Martin, Dojan, Thomas, Ungeheuer, Solveig, Schmalz, Petra, Stass, Angelika, Mildenberger, Vanessa, Goereci, Yasemin, Dunkl, Veronika, Strupp, Julia, Fink, Gereon R., Voltz, Raymond, Stock, Stephanie, Cornely, Oliver, Stahmann, Alexander, Mueller, Anne, Loecherbach, Peter, Burghaus, Lothar, Limmroth, Volker, Bonmann, Eckhard, Gerbershagen, Kathrin, Nelles, Gereon, Joist, Thomas, Haas, Judith, Temmes, Herbert, and Warnke, Clemens

Abstract

Introduction Patients with multiple sclerosis (MS) have complex needs that range from organising one's everyday life to measures of disease-specific therapy monitoring to palliative care. Patients with MS are likely to depend on multiple healthcare providers and various authorities, which are often difficult to coordinate. Thus, they will probably benefit from comprehensive cross-sectoral coordination of services provided by care and case management (CCM). Though studies have shown that case management improves quality of life (QoL), functional status and reduces service use, such benefits have not yet been investigated in severely affected patients with MS. In this explorative phase ll clinical trial, we evaluated a CCM with long-term, cross-sectoral and outreaching services and, in addition, considered the unit of care (patients and caregivers). Methods and analysis Eighty patients with MS and their caregivers will be randomly assigned to either the control (standard care) or the intervention group (standard care plus CCM (for 12 months)). Regular data assessments will be done at baseline and then at 3-month intervals. As primary outcome, we will evaluate patients' QoL. Secondary outcomes are patients' treatment-related risk perception, palliative care needs, anxiety/depression, use of healthcare services, caregivers' burden and QoL, meeting patients' and caregivers' needs, and evaluating the CCM intervention. We will also evaluate CCM through individual interviews and focus groups. The sample size calculation is based on a standardised effect of 0.5, and one baseline and four follow-up assessments (with correlation 0.5). Linear mixed models for repeated measures will be applied to analyse changes in quantitative outcomes over time. Multiple imputation approaches are taken to assess the robustness of the results. The explorative approach (phase ll clinical trial) with embedded qualitative research will allow for the development of a final design for a confirmative

Published
2022

24. Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol

Author

Golla, Heidrun, primary, Dillen, Kim, additional, Hellmich, Martin, additional, Dojan, Thomas, additional, Ungeheuer, Solveig, additional, Schmalz, Petra, additional, Staß, Angelika, additional, Mildenberger, Vanessa, additional, Goereci, Yasemin, additional, Dunkl, Veronika, additional, Strupp, Julia, additional, Fink, Gereon R, additional, Voltz, Raymond, additional, Stock, Stephanie, additional, Cornely, Oliver, additional, Stahmann, Alexander, additional, Müller, Anne, additional, Löcherbach, Peter, additional, Burghaus, Lothar, additional, Limmroth, Volker, additional, Bonmann, Eckhard, additional, Gerbershagen, Kathrin, additional, Nelles, Gereon, additional, Joist, Thomas, additional, Haas, Judith, additional, Temmes, Herbert, additional, and Warnke, Clemens, additional

Published
2022
Full Text
View/download PDF

25. Pathophysiologisch ansetzende Therapie

Author

Alvermann, Sascha, primary, Faiss, Jürgen H., additional, Haas, Judith, additional, Hoffmann, Frank, additional, Köhler, Wolfgang, additional, Martin, Roland, additional, Pöhlau, Dieter, additional, Schippling, Sven, additional, and Stangel, Martin, additional

Published
2015
Full Text
View/download PDF

26. Autorenverzeichnis

Author

Aktas, Orhan, primary, Alvermann, Sascha, additional, Brück, Wolfgang, additional, Faiss, Jürgen H., additional, Fitzner, Brit, additional, Flachenecker, Peter, additional, Gärtner, Jutta, additional, Garten, Lars, additional, Gerken, Jeanine, additional, Greiner, Wolfgang, additional, Haas, Judith, additional, Hardt, Cornelia, additional, Haupts, Michael, additional, Hecker, Michael, additional, Hoffmann, Frank A., additional, Hoppenworth, Uwe, additional, Huppke, Peter, additional, Kern, Raimar, additional, Köhler, Wolfgang, additional, Krumbholz, Markus, additional, Kunkel, Annett, additional, Linke, Ernst, additional, Littig, Eva, additional, Martin, Roland, additional, Meinl, Edgar, additional, Pitschnau-Michel, Dorothea, additional, Pöhlau, Dieter, additional, Reinshagen, Alexander, additional, Rieckmann, Peter, additional, Sailer, Michael, additional, Schifferdecker, Michael, additional, Schipper, Sabine, additional, Schippling, Sven, additional, Manfred Schmidt, Rudolf, additional, Scholz, Stefan, additional, Sokol, Christina, additional, Stadelmann-Nessler, Christine, additional, Stangel, Martin, additional, Tumani, Hayrettin, additional, Zettl, Uwe K., additional, Ziemssen, Tjalf, additional, Zimmermann, Klaus, additional, and Zipp, Frauke, additional

Published
2015
Full Text
View/download PDF

29. sj-docx-1-tan-10.1177_17562864211048336 – Supplemental material for Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis

Author

Frahm, Niklas, Peters, Melanie, Bätzing, Jörg, Ellenberger, David, Akmatov, Manas K., Haas, Judith, Rommer, Paulus S., Stahmann, Alexander, Zettl, Uwe K., and Holstiege, Jakob

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-tan-10.1177_17562864211048336 for Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis by Niklas Frahm, Melanie Peters, Jörg Bätzing, David Ellenberger, Manas K. Akmatov, Judith Haas, Paulus S. Rommer, Alexander Stahmann, Uwe K. Zettl and Jakob Holstiege in Therapeutic Advances in Neurological Disorders

Published
2021
Full Text
View/download PDF

31. The story of aggressive multiple sclerosis

Author

Fneish, Firas, Berger, Klaus, Flachenecker, Peter, Friede, Tim, Haas, Judith, Hellwig, Kerstin, Kleinschnitz, Christoph, Paul, Friedemann, D Pöhlau, Rienhoff, Otto, Rommer, Paulus S, Warnke, Clemens, Stahmann, Alexander, Zettl, Uwe K., and Ellenberger, David

Published
2020
Full Text
View/download PDF

33. Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration

Author

Ellenberger, David, Flachenecker, Peter, Haas, Judith, Hellwig, Kerstin, Paul, Friedemann, Stahmann, Alexander, Warnke, Clemens, Zettl, Uwe K., Rommer, Paulus S., Ellenberger, David, Flachenecker, Peter, Haas, Judith, Hellwig, Kerstin, Paul, Friedemann, Stahmann, Alexander, Warnke, Clemens, Zettl, Uwe K., and Rommer, Paulus S.

Abstract

Background: Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disease with an unpredictable course that has a broad clinical spectrum and progresses over time. If a person with MS (PwMS) shows overall mild to moderate disability even after a long duration of disease, the term benign MS (BMS) is used. However, there is currently no generally accepted definition of BMS. Most definitions are based on EDSS in connection with disease duration, i.e. EDSS <= 3.0 after 15 years' disease duration. The question arises whether focusing on EDSS alone is adequate for classifying the disease course taking into account that 'hidden' or 'soft' symptoms are not sufficiently covered by this instrument. The aims of the study are to assess the prevalence of BMS in one of the largest patient cohorts, to describe the prevalence of patients without disabilities and to assess the further disability progression of these patients over another 15 years. Methods: Based on data exported from the German MS Registry, PwMS with a disease duration of 15 years or more were included in the analyses. PwMS were divided into BMS (EDSS <= 3.0) or non-benign (NBMS, EDSS 3.0). Results: Out of 31,824 PwMS included in the German MS Register, we identified 10,874 patients with a disease duration >= 15 years of whom 4,511 (42%) showed an EDSS <= 3.0 fulfilling the criterion of benign MS. In the subgroup with EDSS measured exactly at 15 years' disease duration, the proportion was 54%. This proportion decreased continuously with increasing disease duration and fell to 30% after 30 years. Female sex (hazard ratio [HR]: 0.84) was associated with BMS, while a progressive (HR: 2.09) and late disease onset (HR: 1.29) were associated with NBMS (p<0.001). With a more rigorous definition of BMS (EDSS <= 1.0, absence of disability, and active employment), only 580 (13%) of the initial BMS remained 'benign'. Conclusion: Our data propose an alternative definition (EDSS <= 1.0, absence from any disability

Published
2020

41. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data

Author

Ohlmeier, Christoph, primary, Gothe, Holger, additional, Haas, Judith, additional, Osowski, Ulrike, additional, Weinhold, Carina, additional, Blauwitz, Sarah, additional, Schmedt, Niklas, additional, Galetzka, Wolfgang, additional, Berkemeier, Fabian, additional, Tackenberg, Björn, additional, and Stangel, Martin, additional

Published
2020
Full Text
View/download PDF

44. Autorinnen und Autoren

Author

Aktas, Orhan, primary, Block, Anja, additional, Bodammer, Nils, additional, Brück, Wolfgang, additional, Faiss, Jürgen H., additional, Feucht, Jeanine, additional, Flachenecker, Peter, additional, Haas, Judith, additional, Hanefeld, Folker, additional, and Hardt, Cornelia, additional

Published
2006
Full Text
View/download PDF

45. Pathophysiologisch ansetzende Therapie

Author

HOFFMANN, FRANK A., primary, AKTAS, ORHAN, additional, HAAS, JUDITH, additional, HARZHEIM, MICHAEL, additional, HOFFMANN, VOLKER, additional, KALLWEIT, ULF, additional, KÖHLER, JÜRGEN, additional, PÖHLAU, DIETER, additional, and ZIPP, FRAUKE, additional

Published
2006
Full Text
View/download PDF

46. Interaktive Webplattform zum EmPOWERment bei Multipler Sklerose (POWER@MS) - Eine randomisiert kontrollierte Studie mit Prozessevaluation zum Einfluss verhaltens- und webbasierter Interventionen auf die entzündliche Krankheitsaktivität bei Erstbetroffenen

Author

Krause, Nicole, Rahn, Anne Christin, Köpke, Sascha, Friede, Tim, Icks, Andrea, Focke, Klaus, Haas, Judith, van de Loo, Markus, Riemann-Lorenz, Karin, Pöttgen, Jana, Stellmann, Jan-Patrick, Gold, Stefan, and Heesen, Christoph

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund/Fragestellung: Multiple Sklerose (MS) ist eine entzündliche und degenerative Erkrankung des zentralen Nervensystems, die vor allem junge Erwachsene betrifft. Verunsicherung und psychischer Stress durch die Diagnose wirken sich möglicherweise negativ auf den Krankheitsverlauf[zum vollständigen Text gelangen Sie über die oben angegebene URL], EbM und Digitale Transformation in der Medizin; 20. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2019

47. Is benign MS 'benign'

Author

Ellenberger, David, Flachenecker, Peter, Eichstädt, Kerstin, Haas, Judith, Kleinschnitz, Christoph, Pöhlau, Dieter, Rienhoff, Otto, Rommer, Paulus S, Zettl, Uwe K, and Stahmann, Alexander

Published
2019
Full Text
View/download PDF

50. Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Author

Burt, Richard K., Cohen, Bruce, Rose, John, Petersen, Finn, Oyama, Yu, Stefoski, Dusan, Katsamakis, George, Carrier, Ewa, Kozak, Tomas, Muraro, Paolo A., Martin, Roland, Hintzen, Roger, Slavin, Shimon, Karussis, Dimitrios, Haggiag, Shalom, Voltarelli, Julio C., Ellison, George W., Jovanovic, Borko, Popat, Uday, McGuirk, Joseph, Statkute, Laisvyde, Verda, Larissa, Haas, Judith, and Arnold, Renate

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results